Omeros Beats Q3 Estimates as YARTEMLEA Sales Rise
Omeros reported third-quarter 2026 earnings of $0.06 per share, beating the consensus estimate of a loss of $0.05 per share and improving on a loss of $0.19 per share a year earlier. Sales of its transplant complication treatment YARTEMLEA rose year over year.
The company recorded a second consecutive quarter of positive operating cash flow, but a non-cash adjustment related to its convertible notes pushed it to a net loss for the period.
The quarter marks a swing from the company's recent full-year results: in fiscal 2025, Omeros reported a net loss of 3.4 million USD and diluted EPS of -0.05 USD.